Loading...
XNAS
MDWD
Market cap205mUSD
Jun 23, Last price  
18.99USD
1D
-0.52%
1Q
13.99%
Jan 2017
-40.76%
IPO
-85.06%
Name

Mediwound Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
10.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.73%
Rev. gr., 5y
-8.65%
Revenues
20m
+8.22%
000259,000601,0001,558,0002,496,0003,401,00031,789,00021,763,00023,763,00026,496,00018,686,00020,222,000
Net income
-30m
L+350.03%
-6,169,00010,940,000-15,351,000-18,875,000-22,088,000-18,885,000-22,149,000-1,057,0003,718,000-9,601,000-13,551,000-19,599,000-6,716,000-30,224,000
CFO
-14m
L+30.19%
-2,960,000-4,728,000-9,740,000-16,493,000-19,601,000-16,445,000-16,455,000-12,154,0008,289,000-6,895,000-8,916,000-11,885,000-10,465,000-13,624,000
Earnings
Aug 12, 2025

Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
URL
https://www.mediwound.com/
IPO date
Mar 20, 2014
Employees
83
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
20,222
8.22%
18,686
-29.48%
26,496
11.50%
Cost of revenue
39,376
33,952
33,883
Unusual Expense (Income)
NOPBT
(19,154)
(15,266)
(7,387)
NOPBT Margin
Operating Taxes
61
185
78
Tax Rate
NOPAT
(19,215)
(15,451)
(7,465)
Net income
(30,224)
350.03%
(6,716)
-65.73%
(19,599)
44.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
22,165
24,909
38,380
BB yield
-12.50%
-27.17%
-57.05%
Debt
Debt current
532
Long-term debt
13,026
12,700
1,692
Deferred revenue
736
Other long-term liabilities
8,553
17,685
26,199
Net debt
3,871
(29,331)
(32,035)
Cash flow
Cash from operating activities
(13,624)
(10,465)
(11,885)
CAPEX
(6,273)
(6,464)
(555)
Cash from investing activities
(8,397)
(34,321)
(481)
Cash from financing activities
19,394
22,917
35,764
FCF
(40,551)
(17,851)
(16,965)
Balance
Cash
9,155
41,541
33,895
Long term investments
490
364
Excess cash
8,144
41,097
32,934
Stockholders' equity
(204,842)
(174,656)
(167,968)
Invested Capital
251,797
230,286
206,459
ROIC
ROCE
EV
Common stock shares outstanding
9,960
9,013
4,987
Price
17.80
75.02%
10.17
-24.61%
13.49
-18.34%
Market cap
177,283
93.41%
91,664
36.25%
67,276
4.63%
EV
181,154
62,333
35,241
EBITDA
(17,671)
(13,963)
(6,115)
EV/EBITDA
Interest
752
427
8,918
Interest/NOPBT